Vertex Ventures HC invests in various sectors of the healthcare industry, including biopharmaceuticals, medical devices and digital health.

Their portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth.

With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. They take an active role in our portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. Their global investment professionals bring deep scientific, medical and business knowledge to every investment they make.

Vertex Ventures HC

Entrepreneur in Residence

Venture Partner

Senior Associate

Sonoma BioTherapeutics raised $265000000 on 2021-08-04 in Series B

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Sonoma Biotherapeutics, Inc.

Earlens Corporation raised $73000000 on 2017-06-05 in Series C

Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.

EarLens

Obsidian Therapeutics raised $115000000 on 2021-09-09 in Series B

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Obsidian Therapeutics, Inc.

Obsidian Therapeutics raised $49500000 on 2017-12-06 in Series A

Boundless Bio raised $100000000 on 2023-05-16 in Series C

Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.

Boundless Bio, Inc.

Earlens Corporation raised $87000000 on 2018-10-22 in Series D

Nuvaira raised $40000000 on 2014-04-03 in Series D

Nuvaira, Inc. develops medical devices to treat obstructive lung diseases. It offers Lung Denervation System, a novel, catheter-based system designed to treat airway nerve hyperactivity and to address chronic obstructive pulmonary diseases by treating overactive airway nerves during a minimally invasive procedure that targets the parasympathetic innervation of the lungs. Nuvaira, Inc. was formerly known as Holaira, Inc. and changed its name to Nuvaira, Inc. in June 2017. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

Nuvaira

Ivantis raised $25000000 on 2014-09-23 in Series B

Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma.  It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma.  As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.

Ivantis Inc.

Twentyeight-Seven Therapeutics raised $15000000 on 2019-05-09 in Series A

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Twentyeight-Seven, Inc.

Allay Therapeutics raised $60000000 on 2021-09-15 in Series C

Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States.

Allay Therapeutics

Epirium Bio raised $85000000 on 2019-12-18 in Series A

Cardero Therapeutics is a start-up pharmaceutical company that is developing a novel class of therapeutics that induces the formation of new mitochondria (mitochondrial biogenesis) and enhances mitochondrial function in response to metabolic demand. Chronic depletion of mitochondria, the principal source of cellular ATP, has been directly linked to the progression of heart failure, sarcopenia, and neurodegeneration. Cardero Therapeutics is collaborating with numerous academic medical centers to advance novel drug candidates structurally based on a newly discovered human hormone that appears to fundamentally regulate mitochondrial density and function in all tissues. Cardero Therapeutics believes that enhancing myocyte bioenergetics will comprise an innovative therapeutic approach complementary to currently available cardiovascular drugs. The company’s clinical development focus is the lethal cardiomyopathy associated with orphan diseases characterized by loss of mitochondria in muscle and heart, resulting in heart failure that is poorly responsive to current medical interventions. Initial clinical trials are directed toward Duchenne muscular dystrophy and Friedreich’s ataxia.

Cardero Therapeutics

NeuSpera Medical raised $65000000 on 2021-07-20 in Series C

NeuSpera Medical Inc. develops and manufactures ultra-miniaturized implantable devices for neuromodulation therapy. Its Neuspera Mid-Field Powering technology uses the body as a natural waveguide to direct energy. NeuSpera Medical Inc. was formerly known as Vivonda Medical Incorporated. The company was incorporated in 2013 and is based in San Jose, California.

NeuSpera Medical

Elevation Oncology raised $65000000 on 2020-11-18 in Series B

Elevation Oncology, Inc., a biotechnology company, focuses on the development of precision medicines for patients with genomically defined cancers. It offers drugs that inhibit the specific alterations identified as drivers of cancer; and treats solid tumors with the NRG1 genomic fusion. Elevation Oncology, Inc. was formerly known as 14ner Oncology, Inc. The company was incorporated in 2019 and is based in New York, New York.

Elevation Oncology

Bicycle Therapeutics raised $52000000 on 2018-09-03 in Series B

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Bicycle Therapeutics

Visterra raised $23100000 on 2016-06-01 in Series C

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Visterra

Innoventure raised an undisclosed amount on 2016-07-05 in Series A

Innoventure is a startup medical device accelerator which brings US/EU medtech assets to China and get through the local regulatory path to develop further value.

Innoventure

Twentyeight-Seven Therapeutics raised $65000000 on 2018-09-06 in Series A

SENSIMED raised $8355789 on 2013-07-10 in Series C

Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. 

Sensimed is now focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.

Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.

SENSIMED

Earlens Corporation raised $34000000 on 2016-06-16 in Series C

Palleon Pharmaceuticals raised $100000000 on 2020-09-17 in Series B

Palleon Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. It offers therapeutics to treat cancer and inflammatory diseases. The company also develops drugs for inflammatory diseases, such as autoimmunity and fibrosis. Palleon Pharmaceuticals Inc. was formerly known as Palleon Pharma Inc. and changed its name to Palleon Pharmaceuticals Inc. in February 2017. The company was founded in 2015 and is based in Waltham, Massachusetts.

Palleon Pharmaceuticals

Visterra raised $30000000 on 2014-10-02 in Series B

Twelve raised $35000000 on 2015-04-28 in Series C

Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

Twelve

Palleon Pharmaceuticals raised $47600000 on 2017-10-04 in Series A

BlackThorn Therapeutics raised $76000000 on 2019-06-13 in Series B

BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

Blackthorn Therapeutics, Inc.

Elevation Oncology raised $32500000 on 2020-07-21 in Series A

Visterra raised $23600000 on 2017-10-05 in Series C

Kona Medical raised $10000000 on 2015-09-02 in Debt Financing

Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’s inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.

Kona Medical

Moximed raised $50000000 on 2017-03-16 in Series C

Moximed, Inc. develops a joint preserving option for patients with knee osteoarthritis. The company offers Atlas System, an implantable joint unloader that works like a shock absorber for a patient with medial compartment knee osteoarthritis, or suffering from pain on the medial (inner) side of the knee, or desire to maintain high activity or productivity levels. It serves patients and medical professionals worldwide. Moximed, Inc. was formerly known as ExploraMed NC4, Inc. The company was incorporated in 2006 and is based in Hayward, California.

Moximed

Nuvaira raised $79000000 on 2019-02-11 in Series E

Epirium Bio raised $85000000 on 2019-12-19 in Series A

Epirium Bio, Inc. develops compounds for treatment of cardiovascular diseases and metabolic syndrome. Epirium Bio, Inc. was formerly known as Cardero Therapeutics, Inc. The company was incorporated in 2008 and is based in San Diego, California.

Epirium Bio

Moximed raised $33000000 on 2015-05-07 in Series B